Immunopathological Analysis in a French National Cohort of Membranous Nephropathy
Immunopathological Analysis in a French National Cohort of Membranous Nephropathy (IHMN)
Centre Hospitalier Universitaire de Nice
400 participants
Jul 4, 2020
INTERVENTIONAL
Conditions
Summary
National cohort of all cases of membranous nephropathy (MN) during a 1 year period in France, based on a pathological and/or serological diagnostic, collecting the data on: * incidence of MN * prevalence of anti-PLA2R1 and anti-THSD7A * clinical outcome one year after diagnosis or after relapse (complete remission, partial remission or persistent nephrotic syndrome) * environmental risk factors for the onset of MN * HLA markers * patient care status in France
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Serum samples will be sent for centralised analyses in Nice. On these samples, different analysis will be performed : * anti-PLA2R1 and anti-THSD7A antibodies * anti-PLA2R1 and anti-THSD7A epitopes * HLA typing
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04326218